Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • AEscobar
    Junior Member
    • Jun 2010
    • 5

    #1

    Nested PCR amplicons

    Our PCR protocol requires nested PCR in order to be more sensitive. We would like to amplicon sequence such nested PCR fragments but we were wondering how much 'bias' it would be introduced by the second round PCR? Would this favor amplification of major variants and 'elimination' of the minors just because of the frequency of each variant, thus reducing the complexity (number of haplotypes) after deep sequencing?
    Has anyone tryed amplicon sequence nested amplicons?
    Is it recommended by Roche?
    Last edited by AEscobar; 06-30-2010, 12:31 PM.
  • pmiguel
    Senior Member
    • Aug 2008
    • 2328

    #2
    Roche is extremely circumspect in these matters--they will not have officially offered an opinion one way or another.

    In any case you have articulated a concern. Seems like a reasonable concern to me. You can test whether there is a problem using spike in experiments.

    Or validate any results you see using another method afterwards.
    --
    Phillip

    Comment

    • AEscobar
      Junior Member
      • Jun 2010
      • 5

      #3
      pmiguel

      Thanks for your reply!
      You can test whether there is a problem using spike in experiments.

      Or validate any results you see using another method afterwards.
      Would you mind providing more details about both suggestions?

      Comment

      • pmiguel
        Senior Member
        • Aug 2008
        • 2328

        #4
        Originally posted by AEscobar View Post
        Thanks for your reply!

        Would you mind providing more details about both suggestions?
        Sure. But I am more or less stating the obvious. Please don't expect any deep insights here.

        In a spike in experiment you add known amounts of sample from a known source at at different levels of dilution to your assay. If your assay faithfully reflects those known levels then you have reason to suspect that it will also do so for the samples you wish to test.

        A comprehensive spike in test would likely be difficult to design. So many instead go the validation route. In this route you trust your new, untested, assay only to provide candidates for assays that are known to be reliable. That is, you might use an RNA seq experiment to "scan" through the transcriptomes of your samples under conditions of interest. Then based on an arbitrary threshold (say the 10 transcripts showing the highest variation (fold change) under the conditions you are studying) you choose candidates for further testing. For example test their levels specifically using qPCR.

        The advantage of this method is that you can use powerful new technologies for "descriptive" rather than analytical purposes. Then you don't need to validate the new technologies up front yet you can benefit from their power.

        --
        Phillip

        Comment

        • AEscobar
          Junior Member
          • Jun 2010
          • 5

          #5
          Thanks!

          We are already designing an experiment where we will be using some of our plasmids as controls.

          Comment

          Latest Articles

          Collapse

          • SEQadmin2
            Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
            by SEQadmin2



            Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

            Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
            ...
            Yesterday, 09:55 AM
          • SEQadmin2
            New Genomics Technologies Take Aim at Long-Standing Limits
            by SEQadmin2


            Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

            We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
            ...
            09-28-2026, 10:25 AM

          ad_right_rmr

          Collapse

          News

          Collapse

          Topics Statistics Last Post
          Started by SEQadmin2, Today, 10:52 AM
          0 responses
          8 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, Yesterday, 05:39 AM
          0 responses
          15 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 10-13-2026, 09:56 AM
          0 responses
          15 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 10-09-2026, 11:14 AM
          0 responses
          27 views
          0 reactions
          Last Post SEQadmin2  
          Working...